ERNAW
Ernexa Therapeutics Inc. WarrantsNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
2.56
52W High
$0.23
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Ernexa Therapeutics Inc. Warrants
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 1,000 |
| Gross Profit (TTM) | 1,000 |
| EBITDA | $-11.69M |
| Operating Margin | 0.00% |
| Return on Equity | -320.70% |
| Return on Assets | -105.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.73 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $1.22M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ERNAW and any ticker you trade — then tracks every position and per-strategy win rate.
Data last updated: 8/18/2026